The Great Phar­ma Brex­it? An End­points News snap poll finds most life sci­ences in­sid­ers pre­dict­ing a de­ba­cle for the in­dus­try

Per­cep­tions mat­ter, es­pe­cial­ly when opin­ions about the fu­ture are be­ing formed in an in­dus­try that holds the key to growth where it’s want­ed most. And right now the glob­al bio­phar­ma busi­ness sees Brex­it do­ing far more harm to bio­phar­ma in the UK than good.

By large mar­gins.

Fol­low­ing up on a sto­ry we ran late last week on one in­dus­try poll re­gard­ing Brex­it — at a time the UK’s rocky de­par­ture from the EU had blown in­to a full fledged po­lit­i­cal cri­sis — we de­cid­ed it would be fun to run a snap sur­vey of our own among read­ers and Twit­ter fol­low­ers to get a broad look at the in­dus­try’s view of Brex­it’s im­pact on drug de­vel­op­ment work and biotech cre­ation — a key field for the is­land econ­o­my.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER